Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Vaso-Occlusive Crises 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Anemia, Sickle Cell 1

Interventions

Bevacizumab 9Oxaliplatin 7Irinotecan 6Fluorouracil 6Nivolumab 5Leucovorin 5Cetuximab 5Capecitabine 5pembrolizumab 4Sunitinib 4IFL protocol 4Drug Therapy 4Cisplatin 4encorafenib 3Pemetrexed 3Gemcitabine 3Folfox protocol 35,10-methylenetetrahydrofolic acid 3trebananib 2trastuzumab deruxtecan 2amminedichloro(2-methylpyridine)platinum(II) 2Ocoxin 2N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 2Levoleucovorin 2IDRX-42 2CGX1321 2130-nm albumin-bound paclitaxel 2zanidatamab 1ulixertinib 1tivozanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Gastrointestinal Neoplasms × Glutamine × Clear all
NCT00455247 2013-06-05

Efficacy of an Oral Formula in Prevention of Anti-cancer Therapy Side Effects

Société des Produits Nestlé (SPN)

Phase 3 Completed
Gastrointestinal

Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡